Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0
Journal of Clinical Oncology · 01.03.2026 · 44 (7)
DOI: 10.1200/jco-25-02825 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2026. Verfasst von Joshua E Reuss und 37 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University, Washington, DC. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 116 Literaturangaben.
Abstract (Originalsprache)
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Six new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
Autor:innen und Institutionen
- Georgetown University, Washington, DC.
- University of California San Diego Moores Cancer Center, San Diego, CA.
- American Society of Clinical Oncology (ASCO), Alexandria, VA.
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI.
- Confluence Health Wenatchee Valley Hospital and Clinics, Wenatchee, WA.
- Texas Oncology, San Antonio, TX.
ORCID-Profile: Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, Amith Ahluwalia, Krishna Alluri, Ibrahim Hanna Azar, Toby Campbell, Greg Durm, Jill Feldman, Narjust Florez, Janet Freeman-Daily, Naoki Furuya, Shirish Gadgeel, Balazs Halmos, Hidehito Horinouchi, Sara Kuruvilla, Gary R Macvicar, Deebya Raj Mishra, Jarushka Naidoo, Dwight H Owen, Bruna Pellini, Carolyn J Presley, Angel Qin, Logan Roof, Erin L Schenk, Lecia Sequist, Navneet Singh, Ana I Velazquez, Paul Wheatley Price, Sonam Puri, Natasha B Leighl
Zitieren
APA
Reuss, J. E., Bazhenova, L., Ismaila, N., Abu Rous, F., Ahluwalia, A., Alluri, K., Azar, I. H., Campbell, T., Durm, G., Feldman, J., Florez, N., Freeman-Daily, J., Furuya, N., Gadgeel, S., Halmos, B., Horinouchi, H., Kuruvilla, S., Macvicar, G. R., Malhotra, N., …, & Leighl, N. B. (2026). Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology, 44(7). https://doi.org/10.1200/jco-25-02825
Vancouver
Reuss JE, Bazhenova L, Ismaila N, Abu Rous F, Ahluwalia A, Alluri K, et al. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology. 2026;44(7). doi:10.1200/jco-25-02825
BibTeX
@article{Reuss2026,
author = {Reuss, Joshua E and Bazhenova, Lyudmila and Ismaila, Nofisat and Abu Rous, Fawzi and Ahluwalia, Amith and Alluri, Krishna and Azar, Ibrahim Hanna and Campbell, Toby and Durm, Greg and Feldman, Jill and Florez, Narjust and Freeman-Daily, Janet and Furuya, Naoki and Gadgeel, Shirish and Halmos, Balazs and Horinouchi, Hidehito and Kuruvilla, Sara and Macvicar, Gary R and Malhotra, Narinder and Marrone, Kristen Ashley and Mishra, Deebya Raj and Mullane, Michael and Naidoo, Jarushka and Owen, Dwight H and Pellini, Bruna and Presley, Carolyn J and Qin, Angel and Roof, Logan and Schenk, Erin L and Sequist, Lecia and Singh, Navneet and Singhi, Eric K and Suga, Jennifer Marie and Velazquez, Ana I and Wang, Yubao and Wheatley Price, Paul and Puri, Sonam and Leighl, Natasha B},
title = {Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {7},
doi = {10.1200/jco-25-02825}
}
EUVIMED